Literature DB >> 1551178

Variability in the pharmacokinetics of epirubicin: a population analysis.

J R Wade1, A W Kelman, D J Kerr, J Robert, B Whiting.   

Abstract

Population pharmacokinetic analysis of the anticancer agent epirubicin was carried out using the program NONMEM. Data were available from 36 patients aged 20-73 years, of whom 23 were women. All subjects exhibited normal liver and renal function. Epirubicin was given as a short-term i.v. infusion over the dose range of 25-100 mg/m2, and an average of 11 plasma samples/subject were taken for a period of up to 72 h after each dose. A Two compartment model was fitted to the data, characterised by the parameters clearance, volume of the central compartment, alpha and beta. Clearance was tested as a linear function of various demographic and/or biochemical features. A significant proportion of the variability in clearance could be attributed to sex, and also to age in women. For example, a 25-year-old man would display an average clearance of 95 l/h, whereas a 70-year-old woman would exhibit an average clearance of 64 l/h. Such differences in clearance might be important in the selection of epirubicin dose regimens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1551178     DOI: 10.1007/bf00686009

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

Review 1.  Clinical pharmacokinetics-pharmacodynamics of anticancer drugs.

Authors:  W E Evans; M V Relling
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

2.  Pharmacokinetics of anthracyclines.

Authors:  S Eksborg
Journal:  Acta Oncol       Date:  1989       Impact factor: 4.089

Review 3.  Anticancer drug pharmacodynamics.

Authors:  G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Pharmacokinetic studies of 4'-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases.

Authors:  C M Camaggi; E Strocchi; V Tamassia; A Martoni; M Giovannini; G Lafelice; N Canova; D Marraro; A Martini; F Pannuti
Journal:  Cancer Treat Rep       Date:  1982-10

5.  Relationship between systemic 5-FU passage and response in colorectal cancer patients treated with intrahepatic chemotherapy.

Authors:  G Milano; M Namer; J L Boublil; R Khater; M Frenay; A Thyss; J Bourry; C Philip; N Renée; J N Bruneton
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.

Authors:  J H Rodman; M Abromowitch; J A Sinkule; F A Hayes; G K Rivera; W E Evans
Journal:  J Clin Oncol       Date:  1987-07       Impact factor: 44.544

7.  Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients.

Authors:  P Vrignaud; H Eghbali; B Hoerni; A Iliadis; J Robert
Journal:  Eur J Cancer Clin Oncol       Date:  1985-11

8.  Effect of cyclophosphamide pretreatment on the short-term disposition and biliary excretion of adriamycin metabolites in rat.

Authors:  N Hartman; P J Basseches; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

9.  Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect.

Authors:  W E Evans; W R Crom; M Abromowitch; R Dodge; A T Look; W P Bowman; S L George; C H Pui
Journal:  N Engl J Med       Date:  1986-02-20       Impact factor: 91.245

10.  Pharmacokinetics and toxicity of two schedules of high dose epirubicin.

Authors:  S A Tjuljandin; R G Doig; M M Sobol; D M Watson; W P Sheridan; G Morstyn; G Mihaly; M D Green
Journal:  Cancer Res       Date:  1990-08-15       Impact factor: 12.701

View more
  18 in total

Review 1.  Pharmacokinetic-pharmacodynamic guided trial design in oncology.

Authors:  Ch van Kesteren; R A A Mathôt; J H Beijnen; J H M Schellens
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

Review 2.  Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.

Authors:  Anthe S Zandvliet; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

3.  Pharmacokinetics and toxicity of idarubicin in the rat.

Authors:  O Kuhlmann; S Hofmann; M Weiss
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

4.  Relationships among liver and kidney volumes, lean body mass and drug clearance.

Authors:  S Nawaratne; J E Brien; E Seeman; R Fabiny; J Zalcberg; W Cosolo; P Angus; D J Morgan
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

Review 5.  Use of pharmacokinetic-pharmacodynamic relationships in the development of new anthracyclines.

Authors:  J Robert
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis.

Authors:  J R Wade; S L Beal; N C Sambol
Journal:  J Pharmacokinet Biopharm       Date:  1994-04

Review 7.  Effect of age on drug metabolism in women with breast cancer.

Authors:  Jasmeet C Singh; Stuart M Lichtman
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-05       Impact factor: 4.481

Review 8.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

9.  Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry.

Authors:  N A Dobbs; C J Twelves; H Gillies; C A James; P G Harper; R D Rubens
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA.

Authors:  Sibylle Loibl; Dennis Rokitta; Bettina Conrad; Nadia Harbeck; Michaela Wüllner; Mathias Warm; Kathrin Schwedler; Bernd Gerber; Iris Schrader; Holger Eidtmann; Keyur Mehta; Uwe Fuhr; Gunter von Minckwitz
Journal:  Breast Care (Basel)       Date:  2014-07       Impact factor: 2.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.